Evaluation of Programmed Death Ligand 1 (PD-L1) Gene Amplification and Response to Nivolumab Monotherapy in Non–small Cell Lung Cancer

IMPORTANCE: Robust predictors for response to anti–programmed death 1 and its ligand (PD-1/PD-L1) immunotherapy in non–small cell lung cancer (NSCLC) are not fully characterized. OBJECTIVE: To evaluate whether PD-L1 (CD274) copy number gains (CNGs), comprising amplification and polysomy, in pretreat...

Descripción completa

Detalles Bibliográficos
Autores principales: Inoue, Yusuke, Yoshimura, Katsuhiro, Nishimoto, Koji, Inui, Naoki, Karayama, Masato, Yasui, Hideki, Hozumi, Hironao, Suzuki, Yuzo, Furuhashi, Kazuki, Fujisawa, Tomoyuki, Enomoto, Noriyuki, Nakamura, Yutaro, Asada, Kazuhiro, Uto, Tomohiro, Fujii, Masato, Matsui, Takashi, Matsuura, Shun, Hashimoto, Dai, Toyoshima, Mikio, Kusagaya, Hideki, Matsuda, Hiroyuki, Inami, Nao, Kaida, Yusuke, Niwa, Mitsuru, Ito, Yasuhiro, Sugimura, Haruhiko, Suda, Takafumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506518/
https://www.ncbi.nlm.nih.gov/pubmed/32955570
http://dx.doi.org/10.1001/jamanetworkopen.2020.11818

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506518/
https://www.ncbi.nlm.nih.gov/pubmed/32955570
http://dx.doi.org/10.1001/jamanetworkopen.2020.11818

Ejemplares similares